Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
This trial will assess the MTD and RP2D of SOT102 administered as monotherapy (Part A) and in
combination with first-line SoC treatment (mFOLFOX6 with nivolumab and nab-paclitaxel/
gemcitabine; Part B) and efficacy of SOT102 administered as monotherapy (Part C) and in
combination with first-line SoC treatment (Part D) in patients with advanced inoperable or
metastatic gastric/GEJ adenocarcinoma or inoperable or metastatic pancreatic adenocarcinoma.